Clinical Trial Update: A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients [Phase 2]

View source ↗

Summary

Phase 2, single-center study evaluating autologous adoptive cell therapy after a lymphodepleting regimen in metastatic urothelial carcinoma; current status unkn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• autologous adoptive cell therapy

Snippet

Sponsor: Sheba Medical Center | Conditions: Metastatic Urothelial Carcinoma | Phase 2 | Status: UNKNOWN